Monte Rosa Therapeutics Inc. plans a signal-verifying phase II trial next year after making known the positive interim data from an ongoing phase I/II trial testing molecular glue degrader MRT-2359 in combination with androgen receptor (AR) inhibitor Xtandi (enzalutamide, Astellas Pharma Inc.). The investigation targeted heavily pretreated patients with metastatic castration-resistant prostate cancer bearing AR mutations.
Qingdao Putaike Biomedical Technology Co. Ltd. has divulged hydrophobic tag-based degraders comprising heat shock protein 90 (HSP90) ligands covalently linked to an androgen receptor (AR)-targeting moiety through a linker acting as AR degradation inducers reported to be useful for the treatment of acne, androgenic alopecia, hirsutism, metabolic disorders, breast cancer and prostate cancer.
The recommendation by a committee advising the U.K. government that screening for prostate cancer should not be made available to the vast majority of men could benefit companies such as Antegenes OÜ. The Estonia-based company develops polygenic risk score-based testing kits which help clarify an individual's genetic predisposition to specific cancers, providing a more targeted approach.
Cornell University and The General Hospital Corp. (Massachusetts General Hospital) have synthesized conjugates comprising a targeting moiety covalently linked to a radiolabeled metal chelator through a linker acting as positron emission tomography (PET) or single-photon emission computerized tomography (SPECT) imaging agents reported to be useful for diagnosis and treatment of cancer.
Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I trial of its KLK3-targeting radiotherapeutic, RAD-402, for the treatment of metastatic or locally advanced prostate cancer.
Laekna Inc. outlicensed select rights to LAE-002 (afuresertib), an oral pan-AKT kinase inhibitor licensed from Novartis AG in 2018, to Qilu Pharmaceutical Co. Ltd. under a potential ¥2.045 billion (US$287.23 million) deal.
About a month after rolling out positive phase I/II data with its candidate for metastatic, castrate-resistant prostate cancer (mCRPC), Halda Therapeutics Inc. disclosed the plan by Johnson & Johnson (J&J), which is paying to take over the company for $3.05 billion in cash.
Laekna Inc. outlicensed select rights to LAE-002 (afuresertib), an oral pan-AKT kinase inhibitor licensed from Novartis AG in 2018, to Qilu Pharmaceutical Co. Ltd. under a potential ¥2.045 billion (US$287.23 million) deal.
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced prostate cancer is treated by targeted alpha therapies in the radiopharmaceutical space.
